VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Some Key Catalysts Approaching
The obesity stocks are perhaps some of the most discussed and followed stocks in the entire biotechnology sector. The two drugs to receive FDA approval...
Posts Tagged ‘Orexigen Therapeutics Inc. (OREX)’
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Anti-Obesity Stocks Are Attractively Priced
The obesity market was one of the most attractive sectors a year ago, and the shares of companies developing anti-obesity drugs were the pharmaceutical...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA), and How Doctors Actually Diagnose Obesity
The obesity crisis in America is a hotly debated topic. According to the Centers for Disease Control and Prevention, more than 35% of adults in the U....
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Ten Flabbergasting Costs of America’s Obesity Epidemic
Obesity is costing us big time. Three times more Americans are obese now than were in 1960. Six times more Americans are now extremely obese than a half...
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Which Obesity Drug Will Boost Your Portfolio?
In 2012, the FDA approved two obesity drugs for use in the United States. One drug, named “Belviq”, is from Arena Pharmaceuticals, Inc. (NASDAQ...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA), Orexigen Therapeutics, Inc. (OREX): The Big Weight-Drug Wait
“Wait” seems to be the operative word for the obesity drug industry these days. Investors in VIVUS, Inc. (NASDAQ:VVUS) are still waiting...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Is Obesity Really a Dangerous Disease?
Obesity drugmakers Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , VIVUS, Inc. (NASDAQ:VVUS) , and Orexigen Therapeutics, Inc. (NASDAQ:OREX) are three of...
5 Hidden Causes of Obesity: Arena Pharmaceuticals, Inc. (ARNA), VIVUS Inc. (VVUS)
Obesity-drug makers Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS Inc. (NASDAQ:VVUS), and Orexigen Therapeutics, Inc. (NASDAQ:OREX) are three of...
Tick Tock Goes the Obesity Clock: Orexigen Therapeutics, Inc. (OREX), VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)
The message from Orexigen Therapeutics, Inc. (NASDAQ:OREX) during its fourth-quarter conference call yesterday was clear: Everything is proceeding as...
Is the Wait Over? – Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX)
The obesity industry is new on the stock block, but it has already become one of the most followed industries in our market. The two major competitors...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Is There a “First-Mover” Advantage in Biotech?
The early bird gets the worm. Business gurus might not use that old phrase, but many of them tout the principle behind it. They tell anyone who will listen...
3 Humongous Health-Care Stocks Last Week: Orexigen Therapeutics, Inc. (OREX), Optimer Pharmaceuticals, Inc. (OPTR)
While the overall market seemed to be deciding this week whether to keep the rally going or take a break, several stocks in the world of health care left...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals Inc. (ARNA): Just 12,500% More Growth for an Obesity Blockbuster
Talk about huge sales growth! Net sales of VIVUS, Inc. (NASDAQ:VVUS)‘ Qsymia in the fourth quarter were up 4,800% over the third quarter . Of course...
The FDA Made Biotech Investing Harder (But More Lucrative): Johnson & Johnson (JNJ)
The secret to successful biotech investing is to understand how the industry works better than the next guy. Following the crowd is no way to make money...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Will There Ever Be an Obesity Drug Blockbuster?
The obesity drug war is about to begin. Investors are anxiously waiting for the launch of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai‘s...
Arena Pharmaceuticals, Vivus Inc, and the Weight-loss Craze
According to a Centers for Disease Control study earlier this year, about 36 percent of Americans are obese. While this might seem like an investing goldmine...
Daniel Gold’s QVT Financial Raised Stake In $OREX
Daniel Gold’s QVT Financial discloses that it now has 5.29 million shares in Orexigen Therapeutics, Inc. (OREX), corresponding to a 9.82% passive stake...
